792948-19-7 Usage
Uses
Used in Pharmaceutical Industry:
(2S)-methyl 2-(((benzyloxy)carbonyl)(prop-2-yn-1-yl)amino)-4-(methylsulfinyl)butanoate is used as a research compound for the development of new drugs and therapies. Its potential as an inhibitor in certain biochemical pathways makes it a valuable tool in the discovery and design of novel pharmaceutical agents.
Used in Medicinal Chemistry Research:
(2S)-methyl 2-(((benzyloxy)carbonyl)(prop-2-yn-1-yl)amino)-4-(methylsulfinyl)butanoate is used as a key intermediate in the synthesis of complex organic molecules and drug candidates. Its unique structural properties allow researchers to explore its potential in the development of new therapeutic agents and to gain insights into the underlying mechanisms of various diseases.
Used in Drug Discovery:
(2S)-methyl 2-(((benzyloxy)carbonyl)(prop-2-yn-1-yl)amino)-4-(methylsulfinyl)butanoate is used as a starting material or building block in the design and synthesis of new drug candidates. Its potential activity in the treatment of various diseases makes it a promising candidate for further investigation and development in drug discovery programs.
Check Digit Verification of cas no
The CAS Registry Mumber 792948-19-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,9,2,9,4 and 8 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 792948-19:
(8*7)+(7*9)+(6*2)+(5*9)+(4*4)+(3*8)+(2*1)+(1*9)=227
227 % 10 = 7
So 792948-19-7 is a valid CAS Registry Number.
792948-19-7Relevant academic research and scientific papers
ARYL, HETEROARY, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS
-
, (2018/09/21)
Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.
Synthetic study of (+)-anthramycin using ring-closing enyne metathesis and cross-metathesis
Kitamura, Tsuyoshi,Sato, Yoshihiro,Mori, Miwako
, p. 9649 - 9657 (2007/10/03)
Synthesis of (+)-anthramycin was examined. A pyrrolobenzodiazepine skeleton could be synthesized by reductive cyclization of pyrrolidine derivative, which was obtained by enyne metathesis. The conjugated enamide ester part of (+)-anthramycin derivative was constructed by cross-metathesis. Graphical Abstract.
